Header and Body 4

Advantages

  • Specific and effective targeting of nanoparticles to IP tumors
  • Modular design allows delivery of chemotherapeutics, RNAs, and/or imaging molecules
  • Compatible with siRNA or CRISPR-Cas9 gene editing
  • Therapeutic potential for treating platinum-resistant ovarian cancer
  • Compatible with NIR imaging technologies